Drug Repositioning for COVID-19
Abstract
Drug repositioning is a strategy that identifies new uses of approved drugs, to treat conditions different from their original purpose. With the advance of COVID-19 and the declaration of a pandemic; It has become the closest alternative to slow the advance of the virus. Antimalarial, antiviral drugs, antibiotics, glucocorticoids, monoclonal antibodies, among others, are being studied; his findings, although preliminary, could establish a starting point in the search for a solution.
In this article, we present a selection of drugs, of different classes and with potential activity to combat COVID-19, whose trials are ongoing; and as proofs of concept, double blind, event-driven add-on, would allow proposing research that generates results in less time and preserving the quality criteria for drug development and approval by regulatory agencies.
Authors
Downloads
Keywords
- COVID-19
- drug repositioning
- pandemic
- therapeutic alternatives
Author Biography
, Universidad del Valle. Cali, Colombia
Education:
Physiotherapist / Universidad del Cauca
Specialist in Cardiopulmonary Physical Therapy / Universidad del Valle
PhD (c) in Biomedical Sciences / Universidad del Valle
Clinical Training Fellowship / European Respiratory Society - Amsterdam Medical Center
Research Area
Pulmonary Rehabilitation, Pulmonary Hypertension, Drug Repositioning.
https://orcid.org/0000-0002-9129-0183
Recent Articles
Benavides-Cordoba, V., Silva-Medina, M., Varela, M. X., & Palacios, M. (2020). Subchronic
toxicity of the pulmonary hypertension model due to low-dose monocrotaline in rats. Journal of
Pharmacy & Pharmacognosy Research, 8(4), 308-315.
Benavides-Cordoba, V., Aviles, S., Ascuntar, C., Orozco, L., Mosquera, R., & Rivera, J. (2020).
Dual use of bronchodilators versus monotherapy, and its impact on pulmonary rehabilitation in
COPD patients. Pulmonary Pharmacology & Therapeutics, 61, 101898.
Benavides-Cordoba, V., Weil, M. S. M., Castaño, S., & Palacios, M. (2019). Hemodynamical
effects of metformin and sildenafil in the treatment of experimental pulmonary hypertension.
European Respiratory Journal. 54: PA4752
Betancourt-Peña J., Ávila Valencia, J. C., Assis, J. K., Gutiérrez, H. H., & Benavides-Cordoba,
V. (2019). Benefits of Pulmonary Rehabilitation in Patients with COPD with Use and without the
Use of Supplemental Oxygen During Exercise. Current Respiratory Medicine Reviews, 15(4),
281-288.
Ávila-Valencia, J. C., Hurtado-Gutiérrez, H., Benavides-Córdoba, V., & Betancourt-Pena, J.
(2019). Aerobic exercise in patients with heart failure with and without ventricular dysfunction in
a cardiac rehabilitation programme. Revista Colombiana de Cardiología, 26(3), 162-168.
Betancourt-Peña, J., Benavides-Córdoba, V., Avila-Valencia, J. C., & Rosero-Carvajal, H. E.
(2019). Differences Between COPD Patients of a Pulmonary
References
WHO. Coronavirus Disease (COVID-19) - events as they happen 2020 [Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen.
Li G, De Clercq E. Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-50. https://doi.org/10.1038/d41573-020-00016-0
Prompetchara E, Ketloy C, Palaga T. Immune Responses in COVID-19 and Potential Vaccines: Lessons Learned From SARS and MERS Epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1-9.
Della G, Jonsdottir, I. Lewis D. Challenges in Early Clinical Development of Adjuvanted Vaccines. Vaccine. 2015;33:47-51. https://doi.org/10.1016/j.vaccine.2015.02.031
Esch EW. BA, Huh D. Organs-on-chips at the Frontiers of Drug Discovery. Nature reviews Drug discovery. 2015;14(4):248-60. https://doi.org/10.1038/nrd4539
Lythgoe MP., Rhodes CJ., Ghataorhe P., Attard M., Wharton J., Wilkins MR. Why Drugs Fail in Clinical Trials in Pulmonary Arterial Hypertension, and Strategies to Succeed in the Future. Pharmacology & therapeutics. 2016;164:195-203. https://doi.org/10.1016/j.pharmthera.2016.04.012
Waring MJ., Arrowsmith J., Leach AR., Leeson PD., Mandrell S., Owen RM., et al. An Analysis of the Attrition of Drug Candidates From Four Major Pharmaceutical Companies. Nature reviews Drug discovery. 2015;14(7):475-88. https://doi.org/10.1038/nrd4609
Pushpakom S, Iorio F, Eyers P, Escott K, Hopper S, Wells A, et al. Drug Repurposing: Progress, Challenges and Recommendations. Nature reviews Drug discovery. 2019;18(1):41-58. https://doi.org/10.1038/nrd.2018.168
Ashburn T, Thor K. Drug Repositioning: Identifying and Developing New Uses for Existing Drugs. Nature reviews Drug discovery. 2004;3(8):673-83. https://doi.org/10.1038/nrd1468
Minghetti P, Lanati E, Godfrey J, Solà-Morales O, O. W, S. S. From Off-Label to Repurposed Drug in Non-Oncological Rare Diseases: Definition and State of the Art in Selected EU Countries. MAP. 2017;1. https://doi.org/10.5301/maapoc.0000016
Breckenridge A, Jacob R. Overcoming the Legal and Regulatory Barriers to Drug Repurposing. Nature reviews Drug discovery. 2019;18(1). https://doi.org/10.1038/nrd.2018.92
Nosengo N. Can You Teach Old Drugs New Tricks? Nature. 2016;534(7607):314-6. https://doi.org/10.1038/534314a
Corsello S, Bittker J, Liu Z, Gould J, McCarren P, Hirschman J, et al. The Drug Repurposing Hub: A Next-Generation Drug Library and Information Resource. Nat Med. 2017;23(4):405-8. https://doi.org/10.1038/nm.4306
Cha Y, Erez T, Reynolds I, Kumar D, Ross J, Koytiger G, et al. Drug Repurposing From the Perspective of Pharmaceutical Companies. British journal of pharmacology. 2018;175(2):168-80. https://doi.org/10.1111/bph.13798
Sleire L, Førde HE, Netland IA, Leiss L, Skeie BS, PØ. E. Drug Repurposing in Cancer. Pharmacological research. 2017;124. https://doi.org/10.1016/j.phrs.2017.07.013
Chen PC, Liu X, Y. L. Drug Repurposing in Anticancer Reagent Development. Combinatorial chemistry & high throughput screening. 2017;20(5):395-402. https://doi.org/10.2174/1386207319666161226143424
Gilbert DC., Vale C., Haire R., Coyle C., Langley RE. Repurposing Vitamin D as an Anticancer Drug. Clinical oncology (Royal College of Radiologists (Great Britain)). 2016;28(1):36-41. https://doi.org/10.1016/j.clon.2015.10.004
Athauda D., Foltynie T. Drug Repurposing in Parkinson's Disease. CNS drugs. 2018;32(8):747-61. https://doi.org/10.1007/s40263-018-0548-y
Mercorelli B., Palù G., Loregian A. Drug Repurposing for Viral Infectious Diseases: How Far Are We? Trends in microbiology. 2018;26(10):865-76. https://doi.org/10.1016/j.tim.2018.04.004
Konreddy AK., Rani GU., Lee K., Choi Y. Recent Drug-Repurposing-Driven Advances in the Discovery of Novel Antibiotics. Current medicinal chemistry. 2019;26(28):5363-88. https://doi.org/10.2174/0929867325666180706101404
Kruse RL., Vanijcharoenkarn K. Drug Repurposing to Treat Asthma and Allergic Disorders: Progress and Prospects. Allergy. 2018;73(2):313-22. https://doi.org/10.1111/all.13305
Sisignano M., Parnham MJ., Geisslinger G. Drug Repurposing for the Development of Novel Analgesics. Trends in pharmacological sciences. 2016;37(3):172-83. https://doi.org/10.1016/j.tips.2015.11.006
Panchapakesan U., Pollock C. Drug Repurposing in Kidney Disease. Kidney international. 2018;94(1):40-8. https://doi.org/10.1016/j.kint.2017.12.026
Walton GM., Stockley JA., Griffiths D., Sadhra CS., Purvis T., Sapey E. Repurposing Treatments to Enhance Innate Immunity. Can Statins Improve Neutrophil Functions and Clinical Outcomes in COPD? Journal of clinical medicine. 2016;5(10). https://doi.org/10.3390/jcm5100089
George CH., Mitchell AN., Preece R., Bannister ML., Yousef Z. Pleiotropic Mechanisms of Action of Perhexiline in Heart Failure. Expert opinion on therapeutic patents. 2016;26(9):1049-59. https://doi.org/10.1080/13543776.2016.1211111
Korkmaz-Icöz S., Radovits T., Szabó G. Targeting Phosphodiesterase 5 as a Therapeutic Option Against Myocardial Ischaemia/Reperfusion Injury and for Treating Heart Failure. British journal of pharmacology. 2018;175(2):223-31. https://doi.org/10.1111/bph.13749
Fuster V, Chesebro J. Aspirin for Primary Prevention of Coronary Disease. European heart journal. 1995;16 Suppl E. https://doi.org/10.1093/eurheartj/16.suppl_E.16
Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag. 2006;2(4):411-22. https://doi.org/10.2147/vhrm.2006.2.4.411
Baker NC., Ekins S., Williams AJ., Tropsha A. A Bibliometric Review of Drug Repurposing. Drug discovery today. 2018;23(3):661-72. https://doi.org/10.1016/j.drudis.2018.01.018
COVID 19 - List Results - ClinicalTrials.gov 2020 [Available from: https://clinicaltrials.gov/ct2.
Schlitzer M. Malaria Chemotherapeutics Part I: History of Antimalarial Drug Development, Currently Used Therapeutics, and Drugs in Clinical Development. ChemMedChem. 2007;2(7). https://doi.org/10.1002/cmdc.200600240
Activity of a New Antimalarial Agent, Chloroquine (SN 7618). J Am Med Assoc. 1946;130:1069. https://doi.org/10.1001/jama.1946.02870160015006
Keyaerts E, Vijgen L, Maes P, Neyts J, Van M. In Vitro Inhibition of Severe Acute Respiratory Syndrome Coronavirus by Chloroquine. Biochem Biophys Res Commun. 2004;323(1):264-8. https://doi.org/10.1016/j.bbrc.2004.08.085
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine Phosphate Has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies. Biosci Trends. 2020;14(1):72-3. https://doi.org/10.5582/bst.2020.01047
Costedoat-Chalumeau N, Dunogué B, Morel N, Guern V, Guettrot-Imbert G. Hydroxychloroquine: A Multifaceted Treatment in Lupus. Presse Med. 2014;43(6 Pt 2). https://doi.org/10.1016/j.lpm.2014.03.007
PubChem. Hydroxychloroquine Compound Summary 2020 [Available from: https://www.ncbi.nlm.nih.gov/pubmed/.
G H. Hydroxychloroquine: An Update. Lupus. 2018;27(9):1402-3. https://doi.org/10.1177/0961203318787040
Yazdany J, Kim A. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Ann Intern Med. 2020. https://doi.org/10.7326/M20-1334
Zhou D, Dai S, Tong Q. COVID-19: A Recommendation to Examine the Effect of Hydroxychloroquine in Preventing Infection and Progression. J Antimicrob Chemother. 2020. https://doi.org/10.1093/jac/dkaa114
Barbosa J, Kaitis D, Freedman R, Le K, Lin X. Clinical outcomes of hydroxychloroquine in hospitalized p... Bibliovid. 2020(bibliovid-a-302).
Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M, et al. Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. Int J Antimicrob Agents. 2020:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
Cunningham AG, H. Koh, D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020;24:91. https://doi.org/10.1186/s13054-020-2818-6
Lai C, Shih T, Ko W, Tang H, Hsueh P. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus disease-2019 (COVID-19): The Epidemic and the Challenges. Int J Antimicrob Agents. 2020;55(3):105924. https://doi.org/10.1016/j.ijantimicag.2020.105924
Liu Y, Li J, Feng Y. Critical Care Response to a Hospital Outbreak of the 2019-nCoV Infection in Shenzhen, China. Crit Care. 2020;24(1):56. https://doi.org/10.1186/s13054-020-2786-x
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients With Severe Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2007016
Sui J, Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, et al. Evaluation of Human Monoclonal Antibody 80R for Immunoprophylaxis of Severe Acute Respiratory Syndrome by an Animal Study, Epitope Mapping, and Analysis of Spike Variants. J Virol. 2005;79(10):5900-6. https://doi.org/10.1128/JVI.79.10.5900-5906.2005
Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JKC, Fooks AR. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 2013;31(12):1553-9. https://doi.org/10.1016/j.vaccine.2013.01.025
Masters PS. The Molecular Biology of Coronaviruses. Adv Virus Res. 2006;66:193-292. https://doi.org/10.1016/S0065-3527(06)66005-3
Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on Monoclonal Antibody Therapy as Potential Therapeutic Intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10-8.
Zhou Y, Qin Y, Lu Y, Sun F, Yang S, Harypursat V, et al. Effectiveness of Glucocorticoid Therapy in Patients With Severe Novel Coronavirus Pneumonia: Protocol of a Randomized Controlled Trial. Chin Med J. 2020. https://doi.org/10.1097/CM9.0000000000000791
Chen C, Qi F, Shi K, Li Y, Li J, Chen Y, et al. Thalidomide Combined with Low-dose Glucocorticoid in the Treatment of COVID-19 Pneumonia. 2020:020395.
Deftereos S, Siasos G, Giannopoulos G, Vrachatis D, Angelidis C, Giotaki S, et al. The GReek Study in the Effects of Colchicine in COvid-19 Complications Prevention (GRECCO-19 Study): Rationale and Study Design. Hellenic J Cardiol. 2020. https://doi.org/10.1016/j.hjc.2020.03.002
Kupferschmidt K, Cohen J. Race to Find COVID-19 Treatments Accelerates. Science. 2020;367(6485):1412-3. https://doi.org/10.1126/science.367.6485.1412
Rosa S, Santos W. Clinical trials on drug repositioning of COVID-19. Pan American Health Organization. 2020. https://doi.org/10.26633/RPSP.2020.40
Wilson M, Fleming K, Kut iM, Looi L, Lag oN, Ru K. Access to Pathology and Laboratory Medicine Services: A Crucial Gap. Lancet. 2018;391(10133):1927-38. https://doi.org/10.1016/S0140-6736(18)30458-6
COVID-19: what science advisers must do now [Nature Briefing]. Nature Publishing Group; 2020 [updated 2020-03-18. Available from: https://media.nature.com/original/magazine-assets/d41586-020-00772-4/d41586-020-00772-4.pdf.
Global Coalition to Accelerate COVID-19 Clinical Research in Resource-Limited Settings. Lancet. 2020.
Fact sheet for health care providers emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of Covid-19 in certain hospitalized patients, (2020).
Charles H., Evans J, Suzanne T. Statistical Approaches to Analysis of Small Clinical Trials [Text]: National Academies Press (US); 2001. Available from: https://www.ncbi.nlm.nih.gov/pubmed/.
Brody T. Clinical Trials - 2nd Edition: Elsevier; 2016. Available from: https://www.elsevier.com/books/clinical-trials/brody/978-0-12-804217-5.
Mills A., Durepos G., Wiebe E. Event-Driven Research. 2010. In: Encyclopedia of Case Study Research [Internet]. Available from: https://methods.sagepub.com/reference/encyc-of-case-study-research/n133.xml. https://doi.org/10.4135/9781412957397
Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2 - Mesenchymal Stem Cells Improves the Outcome of Patients With COVID-19 Pneumonia. Aging Dis. 2020;11(2):216-28. https://doi.org/10.14336/AD.2020.0228
Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease 2020 [Available from: https://clinicaltrials.gov/ct2/show/NCT04325893.
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 2020 [Available from: https://clinicaltrials.gov/ct2/show/NCT04315298.
Zimmer C. Scientists Identify 69 Drugs to Test Against the Coronavirus. New York Times. 2020 20200322.
Copyright (c) 2020 Universidad del Valle
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use
